| 0 (0%) | 12-10 13:22 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.86 | 1-year : | 10.35 |
| Resists | First : | 7.58 | Second : | 8.86 |
| Pivot price | 6.69 |
|||
| Supports | First : | 6.45 | Second : | 5.75 |
| MAs | MA(5) : | 7.03 |
MA(20) : | 6.73 |
| MA(100) : | 6.92  |
MA(250) : | 8.88 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 71.5 |
D(3) : | 71.1 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 11.43 | Low : | 5.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABL ] has closed below upper band by 29.8%. Bollinger Bands are 31.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.1 - 7.15 | 7.15 - 7.19 |
| Low: | 6.9 - 6.95 | 6.95 - 7 |
| Close: | 6.93 - 7.01 | 7.01 - 7.08 |
Sun, 10 Dec 2023
Air France takes delivery of 6th A220-300 from ABL Aviation - AviationSource News
Thu, 07 Dec 2023
Oxford Biomedica acquires ABL Europe - BioProcess InsiderBioProcess International - BioProcess Insider
Tue, 05 Dec 2023
Oxford Biomedica shells out 15M euros to acquire ABL Europe - FiercePharma
Tue, 05 Dec 2023
Oxford Biomedica agrees to acquire ABL Europe - Pharmaceutical Technology
Mon, 04 Dec 2023
Oxford Acquires ABL Europe From Institut Mérieux For €15M - Contract Pharma
Mon, 04 Dec 2023
ABL & MGL Cargo cooperate on cancer treatment installation - American Journal of Transportation
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 63 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 97.9 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 44 (K) |
| EPS | -0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.61 |
| Profit Margin | 44.9 % |
| Operating Margin | 21.3 % |
| Return on Assets (ttm) | 10.7 % |
| Return on Equity (ttm) | 27.1 % |
| Qtrly Rev. Growth | 83.5 % |
| Gross Profit (p.s.) | 0.6 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | 0.55 |
| Qtrly Earnings Growth | -92.9 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -77.89 |
| PEG Ratio | 0 |
| Price to Book value | 2.67 |
| Price to Sales | 7.7 |
| Price to Cash Flow | -13.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|